Impact of SARS-CoV-2 Pandemic on Hepatocellular Carcinoma: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Catherine Yang and Version 1 by Maria Guarino.

Worldwide, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) significantly increases mortality and morbidity. The Coronavirus Disease 2019 (COVID-19) outbreak has had a considerable impact on healthcare systems all around the world, having a significant effect on planned patient activity and established care pathways, in order to meet the difficult task of the global pandemic. Patients with hepatocellular carcinoma (HCC) are considered a particularly susceptible population and conceivably at increased risk for severe COVID-19 because of two combined risk factors: chronic advanced liver disease and HCC itself. In these challenging times, it is mandatory to reshape clinical practice in a prompt way to preserve the highest standards of patient care and safety.

  • hepatocellular carcinoma
  • covid-19
  • liver cancer
  • sars-cov-2

1. Introduction

The spread of the global pandemic by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the subsequent coronavirus disease 2019 (COVID-19) has rapidly become a public health concern with several unmet issues. Since the beginning, the European Association for the Study of the Liver (EASL), as well as several national and international Hepatology Societies, has published position papers to provide guidance for physicians involved in the management of patients with chronic liver diseases (CLD) during the COVID-19 pandemic [1]. Nonetheless, during these two years, the COVID-19 outbreak has forced hepatologists to rethink the allocation of their resources and, in the setting of hepatocellular carcinoma (HCC) management, several modifications have been adopted to harbor the crisis and minimize patients’ exposure to the infection, during and after recovery from the pandemic.

2. Risks of COVID-19 and Serious Illness from COVID-19 in Patients with HCC

It is generally known that SARS-CoV-2 infects host cells binding to the cell receptor angiotensin-converting enzyme II (ACE2), widely expressed in the lung, and also in the gastrointestinal tract [2]. In the liver, ACE2 is mainly expressed by cholangiocytes, but the SARS-CoV-2 infection does not lead to bile duct injury. Indeed, histological features, found in liver biopsy, such as microvesicular liver steatosis, mild lobular, and portal activity, closely resemble a drug-induced liver injury (DILI) [3]. Therefore, it is possible to say that interaction with the ACE2 receptor (ACE2R) is the way, used by SARS-CoV-2, to infect host cells, not the way used for liver damage. Liver damage is probably established through virus direct action or an immuno-mediated mechanism and it may involve both healthy people and patients with CLD [2]. It is also known that during the COVID-19 disease there is a ‘cytokine storm’ with high levels of the proinflammatory cytokines (interleukin 1 and 6, tumor necrosis factor, etc.) whose nature is still poorly understood [4]. All these mechanisms involved in liver injuries during COVID-19 infection suggest that it is probably multifactorial damage, including vascular damage, DILI, coagulopathy, a direct cytopathic effect of the virus, as well as an exaggerated systemic immune response [4]. The main biochemical abnormality detected is an elevation in aminotransferase levels, often mild, observed in more than 20% of cases, with a subsequent minimal increase in bilirubin levels (10% of patients), while the increase in gamma-glutamyl transferase and alkaline phosphatase is uncommon [2,5][2][5]. Liver damage is not responsible for high mortality or severe illness in patients with SARS-CoV-2 infection, but it seems that COVID-19 infection may affect liver disease progression [6]. The main mechanism is linked to an exaggerated release of inflammatory cytokines and the activation of the inflammasome pathway in target cells, following SARS-CoV-2 infection, mostly in patients with cirrhosis [6]. In particular, patients with cirrhosis have high overall mortality for COVID-19 (32%), increasing with each Child–Pugh class (patients with CLD without cirrhosis, as well as general population: 8%, Child–Pugh A 19%, Child–Pugh B 35%, Child–Pugh C 51%) [7]. In HCC patients, ACE2R is highly expressed in cancer tissue, and it could make such patients more vulnerable to SARS-CoV-2 infection, even if ACE2R is not the only pathway of infection. More recently, NRP1 (neuropilin-1) has been detected as a facilitating receptor for SARS-CoV-2 infection. Both ACE2R and NRP1 may be overexpressed in liver cancer cells (particularly by nonparenchymal cells, such as Kupffer’s cells, hepatic stellate cells, and liver sinusoidal endothelial cells) and it may increase the risk of SARS-CoV-2 infection in HCC patients. Despite that, in the literature, there was no strong evidence of an increased risk of infection in HCC patients [10][8]. In their study, Fründt et al. [11][9] analyzed the incidence of COVID-19 in patients (outpatients or inpatients) with liver cirrhosis (with or without HCC) demonstrating that the incidence was lower than expected, and that routine medical care does not increase the incidence of infection, thanks to preventive measures. Nonetheless, this study is limited by the single-center design and by the small sample size [11][9]. Therefore, even if a higher incidence of SARS-CoV-2 infection in patients with HCC is doubtful, several studies have demonstrated a worse outcome (in terms of mortality and serious illness) in patients with CLD and in those with HCC [12][10]. In particular, patients with HCC infected by SARS-CoV-2 have an increased risk of complications, intensive care unit (ICU) admission, and lethal outcomes compared to patients without cancer [10][8]. In a French retrospective study, enrolling more than 15,000 patients with CLD (of them, 3693 with alcohol-use disorders), Mallet et al. showed that the 30-day mortality after COVID-19 is significantly increased in patients with alcohol use disorders, alcohol-related liver disease, cirrhosis, and HCC [9][11]. The higher overall mortality in patients with CLD was demonstrated also by a multicentric study conducted in the United States showing that alcohol-related liver disease, decompensated cirrhosis, and HCC were independent risk factors of higher overall mortality with a sevenfold increased risk of death from COVID-19 in HCC patients compared to patients with different CLD [13][12]. Recently, Iavarone et al. showed higher 30-day mortality rates in cirrhotic patients with COVID-19 than in those with bacterial infections (34% vs. 17%), as well as when comparing cirrhotic COVID-19 positive patients vs. non cirrhotic ones (34% vs. 18%), especially for those with pulmonary failure and with worsening liver function at COVID-19 diagnosis [14][13]. Such a higher risk of serious illness increases also considering the cohort of patients with ongoing liver damage as demonstrated by Guler et al. [15][14], observing that patients with HCC and active HCV infection show up with severe COVID-19 (such as pneumonia and severe pulmonary disease).

3. Impact of COVID-19 on HCC Surveillance and Diagnosis

The institution of measures, such as social distancing and stay-at-home orders, implemented to prevent the spread of COVID-19, have adversely affected the routine outpatient care of CLD, including the HCC surveillance, with short- and long-term effects on mortality from liver disease [38][15]. All society guidelines recommend semiannual surveillance for HCC [39[16][17],40], even though the overall worth of HCC screening in cirrhotic patients is still a matter of debate in light of the absence of specific randomized-controlled trials. The aim of HCC surveillance is to decrease HCC-related mortality by promoting very-early tumor detection for giving patients the possibility of curative treatments. Recently, in a systematic review of several cohort studies, Singal et al. showed that HCC semi-annual surveillance is associated with significant improvement in early diagnosis, curative treatment, and overall survival in cirrhotic patients [41][18]. During the COVID-19 pandemic, most health systems postponed elective imaging, including HCC screening. The COVID-19 outbreak has largely limited the medical care of these patients, with consequences ranging from early diagnosis to treatment. As ultrasound surveillance has mainly been delayed indefinitely, the risk of diagnosing HCC at an advanced stage increased in almost 25% of cirrhotic patients [42][19]. An international survey conducted in 76 Liver Units and focused on the impact of COVID-19 on the management of patients with HCC showed that 87% of the centers modified their clinical practice during the COVID-19 pandemic. Particularly, 80.9% of them modified their HCC screening program and 40.8% changed their diagnostic procedures [23][20]. Moreover, six retrospective studies analyzed the delay in the HCC diagnosis during the COVID-19 outbreak [8,43,44,45,46,47][21][22][23][24][25][26]. All of them, except one, showed a significant reduction in HCC diagnosis during the pandemic compared to the periods before COVID-19. Particularly, Mahmud et al. [43][22] demonstrated that the proportion of patients completing HCC surveillance was significantly lower in 2020 vs. 2019 for each analyzed month. In multivariate analysis, increased odds of surveillance were related to age > 60 years, cirrhosis decompensation, and later 2020 month. Similarly, Ribaldone et al. [45][24] showed that the number of HCC diagnoses, in an Italian Tertiary Center, diminished in the periods March–December 2020 and January–October 2021 compared to May 2019–February 2020 due to a reduction in regular ultrasound surveillance. Currently, the AASLD and the EASL recommend continuing HCC surveillance, deferring it by 8–12 weeks during times of limited radiologic capacities such as COVID-19 [1,26][1][27]. However, given the heterogeneous growth pattern of HCC, the choice to postpone surveillance should be evaluated on a case-by-case basis [48][28]. Some authors suggest stratifying the risk of HCC using scores to identify patients at high risk, for whom surveillance should not be postponed [49,50][29][30]. Moreover, due to the elevated risk of COVID-19 exposure associated with the close contact between physician and patient during ultrasound examination, the Asian Pacific Association for the Study of the Liver (APASL) recommends limiting the use of this practice for surveillance, preferring CT (computed tomography) or MRI (magnetic resonance imaging) in patients at high HCC risk [51][31].

4. Impact of COVID-19 on HCC Management and Treatment

The COVID-19 pandemic has tremendously limited the clinical management of HCC patients, with impacts from early diagnosis to treatment. HCC management is intrinsically and particularly complex so that the treatment is ordinarily established by a multidisciplinary tumor board. In addition, during pandemic waves, it becomes mandatory to balance the risk of a deferred tumor diagnosis, precluding potentially curative treatments against the infection risk. Moreover, it must be taken into account that resources usually allocated to cancer care are limited, as a consequence of their redistribution to face the pandemic. Elective hospital admissions were postponed or canceled during the pandemic peak due to low hospital capacity and the conversion of hepatological/gastroenterological units into COVID-19 wards. For example, only a limited number of Italian hepatologists (20%) reported no relevant changes in their daily activity during the first wave. Indeed, more than 50% of hepatological/gastroenterological units were converted into COVID-19 wards, or the number of beds was reduced, due to nurses and medical personnel shortages either for medical leave or reallocation [20,21][32][33]. A similar scenario was reported in other European countries where COVID-19 infection had a high incidence [52,53][34][35]. A significant reduction in daily activity was also reported for outpatient clinics. In different countries, outpatient care and diagnostic procedures were unavailable for a certain time. In addition, a substantial number of patients were fearful of reaching medical facilities for the risk of getting infected. An international survey has reported that almost 90% of centers have modified their clinical practice with a significant reduction in diagnostic procedures and screening programs [23][20]. For this reason, a greater number of centers decided to switch to remote contact (by e-mail or phone) to facilitate the management of patients with CLD or cancer [21,23][20][33]. Despite the limited number of consultations available and the use of telemedicine, patient satisfaction and assistance perception remained high during the pandemic [19,54][36][37]. Telehealth is in fact associated with considerable patient-centered benefits, including reduced harm, decreased charges and costs, and reduced absenteeism for those who work [55][38]. Conversely, HCC treatment options have been insufficiently maintained. Surgical resection and liver transplants (LT) have been the most affected ones due to a shortage of anesthetists and other healthcare workers [56][39]. Munoz-Martinez et al. reported that at least 50% of curative or palliative treatments for HCC were canceled during the pandemic [23][20]. Similar experiences are reported in surveys collected across the world. In Italy, both surgical and non-surgical loco-regional treatments have been decreased (by 44% and 34%, respectively) or suspended (by 44% and 8%, respectively) during the first and second waves of the pandemic [20,52][32][34]. In this regard, a considerable proportion of institutions, over the world, reported delays > 2 months in the treatment of HCC patients and changes in treatment modality, according to BCLC C classification or compared to similar patients managed before the pandemic [28,57][40][41]. All the scientific societies recommend ensuring continuity of care for HCC patients, avoiding treatment delays or interruptions, and maintaining multidisciplinary (MD) tumor boards. In fact, because of the complexity of HCC management, an MD approach is recommended to optimize the care of patients with HCC. It has been well-recognized that an MD approach increases survival as compared with non-MD care [62][42]. Unfortunately, in many parts of the world, MD boards have been discontinued, considering that many hepatological wards were converted to COVID-19 wards or considering the need for social distancing [28,57][40][41]. However, social distancing should not be considered a motif to temporarily abolish MD meetings, as they can be carried on via the web or in person on the basis of the local pandemic situation. Deviations from ‘‘standard’’ treatment should be discussed and validated in an MD tumor meeting. The alternative therapeutic decision, as well as the benefits of the choice and their associated risks, should be discussed with the patient and accurately documented for legal purposes [31][43]. Reshaping HCC management on the basis of available therapeutic resources and the local current pandemic situation has been demonstrated to maintain a high standard of performance, similar to the pre-pandemic period, and to avoid futile delays in the diagnosis and treatment of cancer patients [31][43]. In this changed scenario, bridge therapy played a crucial role. In the case of early-stage HCCs, the capacity of most hospitals for surgical treatment (resection or LT) was reduced because of the limited number of anesthesiologists as well as shortages in ICU beds. Therefore, hepatologists have to carefully select patients who should be prioritized for surgery according to their risk of surgical complications and the need for ICU admission. Comorbidities, advanced age (75 years or greater), underlying cirrhosis, extensive blood transfusions, and the surgical act planned (minor or major hepatectomy, liver segments/sectors concerned/biliary reconstruction) are very well-known risk factors associated with surgical complications and with the risk of ICU admission after surgery [63,64,65][44][45][46]. A laparoscopic approach should be preferred because of its advantages in pulmonary function and length of stay in the hospital [66][47]. When surgery is not feasible or in patients with a high risk of complications, different approaches can be adopted. A delaying strategy relies on strict imaging monitoring in selected cases. A general agreement to postpone the non-urgent treatment of localized HCC by 2–3 months if oncological outcomes are not likely to be affected has been reached [67][48]. The median HCC doubling time was 229 days in a series of 242 HCC patients, with indolent growth mainly observed in large tumors with alpha-fetoprotein levels < 20 ng/mL and in patients with non-viral liver disease [68][49]. On the other hand, hepatologists should keep in mind that a retrospective study by Singal et al. demonstrated that a treatment delay of >3 months was associated with worse overall survival [69][50]. In cases where the HCC treatment cannot be postponed, locoregional approaches, such as radiofrequency/microwave ablation and trans-arterial therapies (Transarterial chemoembolization—TACE or Transarterial radioembolization—TARE), can be used as alternative or bridging methods, until surgery can be performed. In fact, in many centers locoregional treatments did not decrease but sometimes increased, such as in Pisa [27][51] where TACE and TARE were alternative options for patients with delayed treatment. In patients undergoing surgery or locoregional therapy, strict monitoring should be carried out with imaging examinations every 12–16 weeks in the first year and then every 6 months to evaluate treatment response and detect possible HCC recurrence. Delay in the follow-up monitoring >90 days has been demonstrated to be associated with a lower objective response rate in HCC patients [70][52]. In patients with a complete response to treatment and without recurrence for >2 years, imaging tests can be postponed for up to 2 months according to AASLD recommendations [26,71][27][53]. The prognosis of HCC patients mainly depends on both tumor and underlying liver disease stages. For this reason, risk stratification has a crucial role in defining the most appropriate treatment for each patient. In addition, COVID-19 infection manifesting during the post-surgical period is associated with poor outcomes. Notably, a large multicenter study enrolling 1128 COVID-19-positive patients undergoing surgery at 235 hospitals in 24 countries, showed that the overall 30-day mortality rate was 23.8%, and the rate of pulmonary complications was 51.2% [72][54]. During the pandemic, the number of LT was reduced due to the limited availability of anesthesiologists as well as a shortage of donors [28,73,74,75][40][55][56][57]. The United Network for Organ Sharing described a significant reduction in LT (both living and deceased donor liver) as well as an increase in patient delisting because of COVID-19-related issues and a noticeable reduction in the recovery of deceased-donor organs [76][58]. The major guidelines suggest a temporary suspension of elective living donor transplants aiming to protect both the donor and recipient. According to the EASL position paper, living-donor transplants should be defined on a case-by-case evaluation [1]. It is recommended that donors and recipients be both tested for SARS-CoV-2 before LT [1,51][1][31]. Considering the high risk of mortality in patients with cirrhosis [77][59], it is suggested that patients on a waiting list should be vaccinated for COVID-19 [34][60]. According to current recommendations, LT should not be postponed for high-priority HCC patients with a poor prognosis in the short term, such as those with either acute or chronic liver failure, a high MELD score, and HCC above Milan criteria [1,26][1][27]. In patients on waiting lists, when a complete response to bridging therapy is documented, LT may be postponed [78][61]. Cillo et al. demonstrated that, in a time of donor shortage such as the COVID-19 pandemic, the highest survival benefit is obtained in patients within Milano criteria (single HCC 2–5 cm, or 2–3 HCCs each ≤3 cm [79][62]. In these patients, transplants should not be postponed. Bridging therapy [80][63]. In the case of intermediate-stage HCC, TACE still represents the mainstay of treatment. Nonetheless, TACE is a palliative treatment to reach cytoreduction, with the main purpose of controlling the tumor growth for as long as possible. Short-term use of corticosteroids (3 days) should be prescribed in TACE patients except for those with contraindication (e.g., uncontrolled diabetes) in order to reduce post “embolization syndrome” and minimize hospital stay [81][64]. In the elderly (>80 years) and in patients with comorbidities, TACE/TARE might be postponed, minimizing the risk connected to hospitalization, considering the oncological benefit in comparison to the risk of COVID-19 exposure [28][40].
 

References

  1. Boettler, T.; Marjot, T.; Newsome, P.N.; Mondelli, M.U.; Maticic, M.; Cordero, E.; Jalan, R.; Moreau, R.; Cornberg, M.; Berg, T. Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic. JHEP Rep. 2020, 2, 100169.
  2. Téllez, L.; Mateos, R.M.M. COVID-19 and liver disease: An update. Gastroenterol. Hepatol. 2020, 43, 472–480.
  3. Gambato, M.; Burra, P. Clinical implications of COVID-19 in patients with chronic liver disease and liver tumor. Updates Surg. 2020, 72, 237–239.
  4. Dufour, J.-F.; Marjot, T.; Becchetti, C.; Tilg, H. COVID-19 and liver disease. Gut 2022. ahead of print.
  5. Cabibbo, G.; Rizzo, G.E.M.; Stornello, C.; Craxì, A. SARS-CoV-2 infection in patients with a normal or abnormal liver. J. Viral Hepat. 2020, 28, 4–11.
  6. Luo, M.; Ballester, M.P.; Soffientini, U.; Jalan, R.; Mehta, G. SARS-CoV-2 infection and liver involvement. Hepatol. Int. 2022.
  7. Marjot, T.; Moon, A.M.; Cook, J.A.; Abd-Elsalam, S.; Aloman, C.; Armstrong, M.J.; Pose, E.; Brenner, E.J.; Cargill, T.; Catana, M.-A.; et al. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study. J. Hepatol. 2020, 74, 567–577.
  8. Benedicto, A.; García-Kamiruaga, I.; Arteta, B. Neuropilin-1: A feasible link between liver pathologies and COVID-19. World J. Gastroenterol. 2021, 27, 3516–3529.
  9. Fründt, T.; Kuballa, L.; Lütgehetman, M.; Nörz, D.; Arend, H.; Brehm, T.T.; Wiesch, J.S.Z.; Horvatits, T.; Horvatits, K.; Huber, S.; et al. Low incidence of COVID-19 in a prospective cohort of patients with liver cirrhosis and hepatocellular carcinoma treated at a tertiary medical center during the 2020 pandemic. PLoS ONE 2021, 16, e0258450.
  10. Garrido, I.; Liberal, R.; Macedo, G. COVID-19 and liver disease—What we know on 1st May 2020. Aliment. Pharmacol. Ther. 2020, 52, 267–275.
  11. Mallet, V.; Beeker, N.; Bouam, S.; Sogni, P.; Pol, S.; Fontaine, H.; Corouge, M.; Pichard, A.V.; Hollande, C.; Mehiri, L.L. Prognosis of French COVID-19 patients with chronic liver disease: A national retrospective cohort study for 2020. J. Hepatol. 2021, 75, 848–855.
  12. Kim, D.; Adeniji, N.; Latt, N.; Kumar, S.; Bloom, P.P.; Aby, E.S.; Perumalswami, P.; Roytman, M.; Li, M.; Vogel, A.S.; et al. Predictors of Outcomes of COVID-19 in Patients with Chronic Liver Disease: US Multi-center Study. Clin. Gastroenterol. Hepatol. 2020, 19, 1469–1479.e19.
  13. Iavarone, M.; D’Ambrosio, R.; Soria, A.; Triolo, M.; Pugliese, N.; Del Poggio, P.; Perricone, G.; Massironi, S.; Spinetti, A.; Buscarini, E.; et al. High rates of 30-day mortality in patients with cirrhosis and COVID-19. J. Hepatol. 2020, 73, 1063–1071.
  14. Guler-Margaritis, S.; Mercan-Stanciu, A.; Toma, L.; Rusie, D.; Isac, T.; Dodot, M.; Zgura, A.; Bacalbasa, N.; Haineala, B.; Badiu, D.C.; et al. COVID-19 Mid-term Impact on Hepatocellular Carcinoma in Patients with Hepatitis C Chronic Infection. In Vivo 2021, 35, 3377–3383.
  15. Dinmohamed, A.G.; Visser, O.; Verhoeven, R.H.A.; Louwman, M.W.J.; van Nederveen, F.H.; Willems, S.M.; Merkx, M.A.W.; Lemmens, V.E.P.P.; Nagtegaal, I.D.; Siesling, S. Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands. Lancet Oncol. 2020, 21, 750–751.
  16. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol. 2018, 69, 182–236.
  17. Marrero, J.A.; Kulik, L.M.; Sirlin, C.B.; Zhu, A.X.; Finn, R.S.; Abecassis, M.M.; Roberts, L.R.; Heimbach, J.K. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the AASLD. Hepatology 2018, 68, 723–750.
  18. Singal, A.G.; Zhang, E.; Narasimman, M.; Rich, N.E.; Waljee, A.K.; Hoshida, Y.; Yang, J.D.; Reig, M.; Cabibbo, G.; Nahon, P.; et al. HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis. J. Hepatol. 2022, 77, 128–139.
  19. Tapper, E.B.; Asrani, S.K. The COVID-19 pandemic will have a long-lasting impact on the quality of cirrhosis care. J. Hepatol. 2020, 73, 441–445.
  20. Muñoz-Martínez, S.; Sapena, V.; Forner, A.; Nault, J.-C.; Sapisochin, G.; Rimassa, L.; Sangro, B.; Bruix, J.; Sanduzzi-Zamparelli, M.; Hołówko, W.; et al. Assessing the impact of COVID-19 on liver cancer management (CERO-19). JHEP Rep. 2021, 3, 100260.
  21. Kim, N.J.; Rozenberg-Ben-Dror, K.; Jacob, D.A.; Berry, K.; Ioannou, G.N. The COVID-19 Pandemic Highlights Opportunities to Improve Hepatocellular Carcinoma Screening and Diagnosis in a National Health System. Am. J. Gastroenterol. 2021, 117, 678–684.
  22. Mahmud, N.; Kaplan, D.E.; Goldberg, D.S.; Taddei, T.H.; Serper, M. Changes in Hepatocellular Carcinoma Surveillance and Risk Factors for Noncompletion in the Veterans Health Administration Cohort During the Coronavirus Disease 2019 Pandemic. Gastroenterology 2021, 160, 2162–2164.e3.
  23. Toyoda, H.; Huang, D.Q.; Le, M.; Nguyen, M.H. Liver Care and Surveillance: The Global Impact of the COVID-19 Pandemic. Hepatol. Commun. 2020, 4, 1751–1757.
  24. Ribaldone, D.G.; Caviglia, G.P.; Gaia, S.; Rolle, E.; Risso, A.; Campion, D.; Brunocilla, P.R.; Saracco, G.M.; Carucci, P. Effect of COVID-19 Pandemic on Hepatocellular Carcinoma Diagnosis: Results from a Tertiary Care Center in North-West Italy. Curr. Oncol. 2022, 29, 1422–1429.
  25. Perisetti, A.; Kaur, R.; Thandassery, R. Increased Diagnosis of Hepatocellular Carcinoma in Hospitalized Patients with Alcohol Related Hepatitis after the Covid-19 Outbreak: A Global Multi-Center Propensity Matched Analysis. Clin. Gastroenterol. Hepatol. 2021, 19, 2450–2451.e1.
  26. Kuzuu, K.; Misawa, N.; Ashikari, K.; Kessoku, T.; Kato, S.; Hosono, K.; Yoneda, M.; Nonaka, T.; Matsushima, S.; Komatsu, T.; et al. Gastrointestinal Cancer Stage at Diagnosis Before and During the COVID-19 Pandemic in Japan. JAMA Netw. Open 2021, 4, e2126334.
  27. Fix, O.K.; Hameed, B.; Fontana, R.J.; Kwok, R.M.; McGuire, B.M.; Mulligan, D.C.; Pratt, D.S.; Russo, M.W.; Schilsky, M.L.; Verna, E.C.; et al. Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement. Hepatology 2020, 72, 287–304.
  28. Bollipo, S.; Kapuria, D.; Rabiee, A.; Ben-Yakov, G.; Lui, R.N.; Lee, H.W.; Kumar, G.; Siau, K.; Turnes, J.; Dhanasekaran, R. One world, one pandemic, many guidelines: Management of liver diseases during COVID-19. Gut 2020, 69, 1369–1372.
  29. Zeng, G.; Gill, U.S.; Kennedy, P.T.F. Prioritisation and the initiation of HCC surveillance in CHB patients: Lessons to learn from the COVID-19 crisis. Gut 2020, 69, 1907–1912.
  30. Sinharay, R.; Grant, A.J.; Rivett, L.; Blackwell, R.; Mells, G.; Gelson, W. Assessing efficacy of hepatocellular carcinoma prediction scores to prioritise hepatitis B surveillance in the COVID-19 era. GastroHep 2021, 3, 80–87.
  31. Shiina, S.; Gani, R.A.; Yokosuka, O.; Maruyama, H.; Nagamatsu, H.; Payawal, D.A.; Dokmeci, A.K.; Lesmana, L.A.; Tanwandee, T.; Lau, G.; et al. APASL practical recommendations for the management of hepatocellular carcinoma in the era of COVID-19. Hepatol. Int. 2020, 14, 920–929.
  32. Ponziani, F.R.; Aghemo, A.; Cabibbo, G.; Masarone, M.; Montagnese, S.; Petta, S.; Russo, F.P.; Lai, Q.; The AISF COVID-19 survey group. Management of liver disease in Italy after one year of the SARS-CoV-2 pandemic: A web-based survey. Liver Int. 2021, 41, 2228–2232.
  33. Aghemo, A.; Masarone, M.; Montagnese, S.; Petta, S.; Ponziani, F.R.; Russo, F.P. Assessing the impact of COVID-19 on the management of patients with liver diseases: A national survey by the Italian association for the study of the Liver. Dig. Liver Dis. 2020, 52, 937–941.
  34. Balakrishnan, A.; Lesurtel, M.; Siriwardena, A.K.; Heinrich, S.; Serrablo, A.; Besselink, M.G.; Erkan, M.; Andersson, B.; Polak, W.G.; Laurenzi, A.; et al. Delivery of hepato-pancreato-biliary surgery during the COVID-19 pandemic: An European-African Hepato-Pancreato-Biliary Association (E-AHPBA) cross-sectional survey. HPB 2020, 22, 1128–1134.
  35. Crespo, J.; Carrillo, C.F.; Iruzubieta, P.; Hernández-Conde, M.; Rasines, L.; Jorquera, F.; Albillos, A.; Bañares, R.; Mora, P.; Vázquez, I.F.; et al. Massive impact of coronavirus disease 2019 pandemic on gastroenterology and hepatology departments and doctors in Spain. J. Gastroenterol. Hepatol. 2021, 36, 1627–1633.
  36. Guarino, M.; Cossiga, V.; Fiorentino, A.; Pontillo, G.; Morisco, F. Use of Telemedicine for Chronic Liver Disease at a Single Care Center During the COVID-19 Pandemic: Prospective Observational Study. J. Med Internet Res. 2020, 22, e20874.
  37. Pomej, K.; Scheiner, B.; Hartl, L.; Balcar, L.; Meischl, T.; Mandorfer, M.; Reiberger, T.; Muller, C.; Trauner, M.; Pinter, M. COVID-19 pandemic: Impact on the management of patients with hepatocellular carcinoma at a tertiary care hospital. PLoS ONE 2021, 16, e0256544.
  38. John, B.V.; Love, E.; Dahman, B.; Kurbanova, N.; Konjeti, V.R.; Sundaram, L.T.; Deng, Y.; Aubuchon, S.; Heuman, D.; Bajaj, J.S.; et al. Use of telehealth expedites evaluation and listing of patients referred for liver transplantation. Clin. Gastroenterol. Hepatol. 2019, 18, 1822–1830.e4.
  39. Wong, G.L.-H.; Wong, V.W.-S.; Thompson, A.; Jia, J.; Hou, J.; Lesmana, C.R.A.; Susilo, A.; Tanaka, Y.; Chan, W.-K.; Gane, E. Management of patients with liver derangement during the COVID-19 pandemic: An Asia-Pacific position statement. Lancet Gastroenterol. Hepatol. 2020, 5, 776–787.
  40. Iavarone, M.; Sangiovanni, A.; Carrafiello, G.; Rossi, G.; Lampertico, P. Management of hepatocellular carcinoma in the time of COVID-19. Ann. Oncol. 2020, 31, 1084–1085.
  41. Amaddeo, G.; Brustia, R.; Allaire, M.; Lequoy, M.; Hollande, C.; Regnault, H.; Blaise, L.; Ganne-Carrié, N.; Séror, O.; Larrey, E.; et al. Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area. JHEP Rep. 2020, 3, 100199.
  42. Sinn, D.H.; Choi, G.-S.; Park, H.C.; Kim, J.M.; Kim, H.; Song, K.D.; Kang, T.W.; Lee, M.W.; Rhim, H.; Hyun, D.; et al. Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients. PLoS ONE 2019, 14, e0210730.
  43. Iavarone, M.; Antonelli, B.; Ierardi, A.M.; Topa, M.; Sangiovanni, A.; Gori, A.; Oggioni, C.; Rossi, G.; Carrafiello, G.; Lampertico, P. Reshape and secure HCC managing during COVID-19 pandemic: A single centre analysis of four periods in 2020 versus 2019. Liver Int. 2021, 41, 3028–3032.
  44. Kawaguchi, Y.; Fuks, D.; Kokudo, N.; Gayet, B. Difficulty of Laparoscopic Liver Resection: Proposal for a New Classification. Ann. Surg. 2018, 267, 13–17.
  45. Hobeika, C.; Fuks, D.; Cauchy, F.; Goumard, C.; Soubrane, O.; Gayet, B.; Salamé, E.; Cherqui, D.; Vibert, E.; Scatton, O.; et al. Impact of cirrhosis in patients undergoing laparoscopic liver resection in a nationwide multicentre survey. Br. J. Surg. 2020, 107, 268–277.
  46. An, C.; Choi, Y.A.; Choi, D.; Paik, Y.H.; Ahn, S.H.; Kim, M.-J.; Paik, S.W.; Han, K.-H.; Park, M.-S. Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease. Clin. Mol. Hepatol. 2015, 21, 279–286.
  47. Jia, C.; Li, H.; Wen, N.; Chen, J.; Wei, Y.; Li, B. Laparoscopic liver resection: A review of current indications and surgical techniques. Hepatobiliary Surg. Nutr. 2018, 7, 277–288.
  48. Cao, H.T.; Tzeng, C.-W.; Chun, Y.S.; Aloia, T.; Vauthey, J.N. Surgical Management of Localized Hepatocellular Carcinoma in Times of Crisis: A Strategic Approach to Resource Utilization. J. Hepatocell. Carcinoma 2020, 7, 155–158.
  49. Rich, N.E.; John, B.V.; Parikh, N.D.; Rowe, I.; Mehta, N.; Khatri, G.; Thomas, S.M.; Anis, M.; Mendiratta-Lala, M.; Hernandez, C.; et al. Hepatocellular Carcinoma Demonstrates Heterogeneous Growth Patterns in a Multicenter Cohort of Patients with Cirrhosis. Hepatology 2020, 72, 1654–1665.
  50. Singal, A.G.; Waljee, A.K.; Patel, N.; Chen, E.Y.; Tiro, J.; Marrero, J.A.; Yopp, A.C. Therapeutic delays lead to worse survival among patients with hepatocellular carcinoma. J. Natl. Compr. Cancer Netw. 2013, 11, 1101–1108.
  51. Bargellini, I.; Boni, G.; Traino, A.C.; Bozzi, E.; Lorenzoni, G.; Bianchi, F.; Cervelli, R.; Depalo, T.; Crocetti, L.; Volterrani, D.; et al. Management of Liver Tumors during the COVID-19 Pandemic: The Added Value of Selective Internal Radiation Therapy (SIRT). J. Clin. Med. 2021, 10, 4315.
  52. Jin, Z.-C.; Chen, L.; Zhong, B.-Y.; Zhu, H.-D.; Zeng, C.-H.; Li, R.; Guo, J.-H.; He, S.-C.; Deng, G.; Zhu, X.-L.; et al. Impact of COVID-19 Pandemic on Intervals and Outcomes of Repeated Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma. Front. Oncol. 2021, 11, 602700.
  53. Chagas, A.L.; da Fonseca, L.G.; Coelho, F.F.; Saud, L.R.D.C.; Abadala, E.; Andraus, W.; Fiore, L.; Moreira, A.M.; Menezes, M.R.; Carnevale, F.C.; et al. Management of Hepatocellular Carcinoma during the COVID-19 Pandemic—São Paulo Clínicas Liver Cancer Group Multidisciplinary Consensus Statement. Clinics 2020, 75, e2192.
  54. COVIDSurg Collaborative. Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: An international cohort study. Lancet 2020, 396, 27–38.
  55. Chan, S.L.; Kudo, M. Impacts of COVID-19 on Liver Cancers: During and after the Pandemic. Liver Cancer 2020, 9, 491–502.
  56. Maggi, U.; De Carlis, L.; Yiu, D.; Colledan, M.; Regalia, E.; Rossi, G.; Angrisani, M.; Consonni, D.; Fornoni, G.; Piccolo, G.; et al. The impact of the COVID-19 outbreak on liver trans-plantation programs in northern Italy. Am. J. Transplant. 2020, 20, 1840–1848.
  57. Trapani, S.; Masiero, L.; Puoti, F.; Rota, M.C.; Del Manso, M.; Lombardini, L.; Riccardo, F.; Amoroso, A.; Pezzotti, P.; Grossi, P.A.; et al. Incidence and outcome of SARS-CoV-2 infection on solid organ transplantation recipients: A nationwide population-based study. Am. J. Transplant. 2021, 21, 2509–2521.
  58. Merola, J.; Schilsky, M.L.; Mulligan, D.C. The Impact of COVID-19 on Organ Donation, Procurement and Liver Transplantation in the United States. Hepatol. Commun. 2020, 5, 5–11.
  59. Belli, L.S.; Duvoux, C.; Cortesi, P.A.; Facchetti, R.; Iacob, S.; Perricone, G.; Radenne, S.; Conti, S.; Patrono, D.; Berlakovich, G.; et al. COVID-19 in liver transplant candidates: Pretransplant and post-transplant outcomes—An ELITA/ELTR multicentre cohort study. Gut 2021, 70, 1914–1924.
  60. Cornberg, M.; Buti, M.; Eberhardt, C.S.; Grossi, P.A.; Shouval, D. EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients. J. Hepatol. 2021, 74, 944–951.
  61. Kudo, M.; Kurosaki, M.; Ikeda, M.; Aikata, H.; Hiraoka, A.; Torimura, T.; Sakamoto, N. Treatment of hepatocellular carcinoma during the COVID-19 outbreak: The Working Group report of JAMTT-HCC. Hepatol. Res. 2020, 50, 1004–1014.
  62. Cillo, U.; Vitale, A.; Volk, M.; Frigo, A.; Feltracco, P.; Cattelan, A.; Brancaccio, G.; Feltrin, G.; Angeli, P.; Burra, P.; et al. Liver Transplantation for T2 Hepatocellular Carcinoma during the COVID-19 Pandemic: A Novel Model Balancing Individual Benefit against Healthcare Resources. Cancers 2021, 13, 1416.
  63. Management Of HCC During COVID-19: ILCA Guidance. Available online: https://ilca-online.org/news/management-of-hcc-during-covid-19-ilca-guidance (accessed on 1 April 2022).
  64. Chang, L.; Wang, W.; Jiang, N.; Rao, F.; Gong, C.; Wu, P.; Yang, J.; Liu, Z.; Guo, T. Dexamethasone prevents TACE-induced adverse events: A meta-analysis. Medicine 2020, 99, e23191.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
ScholarVision Creations
Feedback